Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran
- 39 Downloads
The optimal treatment for locally advanced GEJ and cardia adenocarcinoma is controversial. Several studies have shown that treating these patients with neoadjuvant chemoradiotherapy followed by surgery leads to survival benefits, and there are also studies that have declared conflicting results. It seems that there is still room for discussion. We calculated the survival rates and pathologic responses in our patients with characteristics which we mentioned above.
Patients with locally advanced, non-metastatic GEJ and cardia adenocarcinomas (only patients with Siewert’s type I and II), who were referred to Imam Khomeini hospital (Institute of cancer) between 2005 and 2014 and received neoadjuvant chemoradiation and underwent surgery were enrolled in this retrospective cohort study. Evaluations were done every 3 months.
Thirty-two patients enrolled in this study. Median follow up time was 23 months (Reverse Kaplan-Meier method). The rates of 1-year survival, 2-year survival, 3-year survival, 4-year survival, and 5-year survival were 75%, 52%, 52%, 37%, and 37%, respectively. No local recurrences occurred among patients; however, four patients experienced distal recurrence in the following locations: two cases (6.3%) in the liver, one case (3.1%) in the lung, and one case (3.1%) in the peritoneum. The rate of complete pathologic response (T0N0) was 21.9%.
Neoadjuvant chemoradiation in patients with locally advanced GEJ and cardia adenocarcinoma will lead to a survival benefit.
KeywordsChemoradiotherapy Esophageal neoplasms Gastrointestinal cancer Iran Neoadjuvant
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006 May;24(14):2137–50. https://doi.org/10.1200/JCO.2005.05.2308.CrossRefPubMedGoogle Scholar
- 7.Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. https://doi.org/10.1016/S1470-2045(11)70142-5.CrossRefGoogle Scholar
- 13.Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PWT, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953–8.CrossRefGoogle Scholar
- 14.Motoori M, Yano M, Yasuda T, Miyata H, Peng Y, Yamasaki M, et al. Early response to neoadjuvant chemotherapy in advanced esophageal cancer evaluated by computed tomography predicts the utility of a second cycle of chemotherapy. Mol Clin Oncol. 2013;1(3):521–6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3916104&tool=pmcentrez&rendertype=abstract CrossRefGoogle Scholar
- 15.Zhou Z, Nimeiri HS, Benson AB. Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer? Ann Transl Med. 2013;1(2):11–6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4200631&tool=pmcentrez&rendertype=abstract PubMedPubMedCentralGoogle Scholar
- 16.Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–33. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12049861 CrossRefGoogle Scholar
- 18.Walsh T et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. 1996;Google Scholar
- 21.Akhavan A, Binesh F, Seifaddiny A. Characteristics and survival rate of patients with gastric and gastroesophageal junction adenocarcinoma in Yazd, Iran. 2013;4(3):125–9.Google Scholar
- 23.Cellini F, Fiore M, Mattiucci G. Gastrointestinal & digestive system radiochemotherapy in the management of gastroesophageal junction tumours: basic evidences in the neoadjuvant setting. 2013;3(4):3–6.Google Scholar
- 27.Sun L, Zhao G, Ding D, Song B, Hou R, Li Y. Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective , comparative study at a single tertiary care institute. 2014;1–5.Google Scholar
- 28.Mirza A, Pritchard S, Welch I. The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas. Int J Surg Oncol. 2013;2013Google Scholar
- 32.Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol. 2007;25(18_suppl):4510. https://doi.org/10.1200/jco.2007.25.18_suppl.4510.CrossRefGoogle Scholar